Elvan Çiftçi, Husnu Erkmen, Emine Bulanik, Barış Metin, Nevzat Tarhan
{"title":"Beta Rhythm Predicts Treatment Response to Deep Transcranial Magnetic Stimulation in Patients with Treatment-Resistant Obsessive-Compulsive Disorder.","authors":"Elvan Çiftçi, Husnu Erkmen, Emine Bulanik, Barış Metin, Nevzat Tarhan","doi":"10.1177/15500594251368432","DOIUrl":null,"url":null,"abstract":"<p><p>IntroductionObsessive-compulsive disorder (OCD) affects 1.1-1.8% of the population, and adult females are more likely to suffer from it. Deep transcranial magnetic stimulation (dTMS) stimulates dorsomedial prefrontal cortex and anterior cingulate cortex - two frontal brain networks implicated in OCD. This study aims to identify a biological marker for beta rhythm that correlates with the treatment response works following dTMS.MethodsA total of 56 right-handed treatment-resistant OCD patients (35 female and 21 male) were retrospectively included in the study which were treated with FDA-approved dTMS protocol by using H7-coil for OCD. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) was used before and after dTMS to determine the severity of OCD symptoms and the responsiveness to therapy. Also, beta oscillations gathered from 19 electrodes quantitative electroencephalogram (QEEG) was assessed as treatment response prediction while controlling age and sex parameters.ResultsWhen controlling for sex and age, the Y-BOCS decline rate was linked to higher pretreatment beta activity in the parietal and occipital regions. In the second step of our analysis, we used a stepwise linear regression analysis to create a model predicting YBOCS decline rate. In this model, age (beta = -0.284, p = 0.030) and pretreatment beta parietal power band (beta = 0.312, p = 0.018) were the predictors.ConclusionAge and pretreatment parietal beta power bands may be used as a biomarker for predicting response to dTMS therapy if confirmed by further studies.</p>","PeriodicalId":93940,"journal":{"name":"Clinical EEG and neuroscience","volume":" ","pages":"15500594251368432"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical EEG and neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/15500594251368432","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
IntroductionObsessive-compulsive disorder (OCD) affects 1.1-1.8% of the population, and adult females are more likely to suffer from it. Deep transcranial magnetic stimulation (dTMS) stimulates dorsomedial prefrontal cortex and anterior cingulate cortex - two frontal brain networks implicated in OCD. This study aims to identify a biological marker for beta rhythm that correlates with the treatment response works following dTMS.MethodsA total of 56 right-handed treatment-resistant OCD patients (35 female and 21 male) were retrospectively included in the study which were treated with FDA-approved dTMS protocol by using H7-coil for OCD. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) was used before and after dTMS to determine the severity of OCD symptoms and the responsiveness to therapy. Also, beta oscillations gathered from 19 electrodes quantitative electroencephalogram (QEEG) was assessed as treatment response prediction while controlling age and sex parameters.ResultsWhen controlling for sex and age, the Y-BOCS decline rate was linked to higher pretreatment beta activity in the parietal and occipital regions. In the second step of our analysis, we used a stepwise linear regression analysis to create a model predicting YBOCS decline rate. In this model, age (beta = -0.284, p = 0.030) and pretreatment beta parietal power band (beta = 0.312, p = 0.018) were the predictors.ConclusionAge and pretreatment parietal beta power bands may be used as a biomarker for predicting response to dTMS therapy if confirmed by further studies.